Drug intelligence / Profile preview

[d-Arg7, d-Lys15, d-Lys23]-esculentin-2CHa(1-30)

Development stage
Preclinical
Lead developer
Ulster University
Modality
Peptides
Administration
Intraperitoneal
01

Overview

[d-Arg7, d-Lys15, d-Lys23]-esculentin-2CHa(1-30) is a synthetic peptide analogue of esculentin-2CHa(1-30), an antimicrobial peptide (AMP) originally isolated from the skin secretions of the edible frog *Rana esculenta* (Pelophylax esculentus). This specific analogue incorporates D-amino acid substitutions at positions 7 (Arginine), 15 (Lysine), and 23 (Lysine) to enhance metabolic stability against proteolytic degradation. In preclinical research, the peptide has demonstrated significant therapeutic potential for the treatment of type 2 diabetes and obesity. It has been shown to reduce body weight and fat mass, lower blood glucose and HbA1c levels, and improve insulin sensitivity and glucose tolerance. Its mechanism of action involves preserving and enhancing pancreatic islet function, promoting beta-cell proliferation, and modulating the expression of key metabolic genes in skeletal muscle and pancreatic tissues, such as GLUT4, IRS1, and PDX1.

Other names
[D-Arg7, D-Lys15, D-Lys23]-esculentin-2CHa(1-30)(D-Arg7, D-Lys15, D-Lys23)-esculentin-2CHa(1-30)
02

Targets

AKT (RAC-alpha serine/threonine-protein kinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)IRS1 (Insulin receptor substrate 1)PDX1 (Pancreas/duodenum homeobox protein 1)SLC2A2 (Solute carrier family 2 facilitated glucose transporter member 2)

Beyond the preview

Go deeper on [d-Arg7, d-Lys15, d-Lys23]-esculentin-2CHa(1-30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [d-Arg7, d-Lys15, d-Lys23]-esculentin-2CHa(1-30).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call